PathoQuest announces enrollment of first patient in IDENTIFY, a prospective clinical study assessing the medico-economic benefit of iDTECT™ Blood for the diagnosis of bloodstream infection in immunocompromised patients

Pour la version en français de ce communiqué de presse : cliquez ici PARIS, FRANCE, May 22, 2018 – PathoQuest, a genomic expert for biologics testing and a leader in improving pathogen identification in clinical biological samples, today announced the...

PathoQuest Achieves CE Mark for the iDTECT™ Blood Test

iDTECT™ Blood is the first NGS-based metagenomics test to be CE-IVD marked for the clinical identification of pathogens from blood samples Click here to view French version of this release PathoQuest, a biotechnology company spun out from Institut Pasteur, today...